Which antipsychotics are exceptions to the guideline to avoid most antipsychotics?

• A. Quetiapine, Clozapine, Pimavanserin
• B. Haloperidol, Chlorpromazine, Olanzapine
• C. Risperidone, Ziprasidone, Aripiprazole
• D. Paliperidone, Lurasidone, Asenapine

Answer: (A)

The concept being tested is why some antipsychotics are considered exceptions to a general guideline that aims to minimize antipsychotic use due to extrapyramidal symptoms (EPS) and related issues. The key is how strongly each drug blocks dopamine D2 receptors.

Quetiapine is a weak D2 antagonist with rapid dissociation from the receptor, so at typical doses it produces very little EPS compared with other antipsychotics. That lower propensity for EPS makes it an exception to the rule against most antipsychotics, especially in patients where EPS would be particularly problematic. It does carry sedation and metabolic risks, and it’s still necessary to monitor for drug interactions and side effects, but its D2 profile explains its relative safety on movement disorders.

Clozapine is unique among antipsychotics for its very low risk of EPS, despite being a potent antipsychotic. Its receptor activity leads to minimal motor side effects, which is why it remains an exception to the general guideline about avoiding most antipsychotics because of EPS concerns. Of course, clozapine requires regular monitoring for agranulocytosis and blood counts, and metabolic effects are still a consideration, but its EPS risk is notably low.

Pimavanserin works differently altogether because it does not block dopamine D2 receptors at all. It is a 5-HT2A inverse agonist, so it does not cause D2-related EPS or prolactin elevation. This mechanism makes it another clear exception to the guideline about avoiding most antipsychotics due to movement disorder risk. It does bring considerations like QT prolongation and limited clinical use outside certain indications, but from an EPS standpoint it stands apart.

In short, these three are considered exceptions because their pharmacologic profiles either produce minimal D2 blockade or none at all, resulting in a much lower risk of extrapyramidal symptoms compared with most other antipsychotics.